Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910728 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00910728 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 65 participants.
The verdict
NCT00910728, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD1480 in the body over a period of time and will indicate whether the drug has a therapeutic effect on myeloproliferative diseases.
Interventions
- DRUG AZD1480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00910728
The ClinicalTrials.gov registry entry for NCT00910728 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD1480 is the first listed.
NCT00910728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00910728 about?
NCT00910728 is a clinical study titled "Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases". This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480. This is the first time the drug has been given to humans and is classed as a first time in man ...
What is the current status of trial NCT00910728?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2009-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00910728?
The interventions under investigation include: AZD1480 (DRUG).
Who is sponsoring clinical trial NCT00910728?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.